This information is intended for use by health professionals

1. Name of the medicinal product

Boots Thrush 1% w/w Cream

Teva Thrush Relief 1% w/w Cream

Lloydspharmacy Thrush Femme 1% w/w Cream

Asda Thrush Relief 1% w/w Cream

Morrisons Thrush Relief 1% w/w Cream

Clotrimazole 1% w/w Cream

Boots Thrush Duo

Boots Thrush Oral Capsule and Cream Duo

Lloyds Pharmacy Thrush Duo

Teva Thrush Duo

Vantage Thrush Duo

2. Qualitative and quantitative composition

Clotrimazole 1% w/w

For excipients see 6.1

3. Pharmaceutical form


A white cream.

4. Clinical particulars
4.1 Therapeutic indications

For the treatment of candidal vulvitis, adjunct to the treatment of candidal vaginitis. It can also be used for treatment of candidal balanitis of the sexual partner.

4.2 Posology and method of administration

Adults (over 16 and under 60 years old)

Apply to the affected area two or three times daily

Candida infections: treat for at least two weeks

Route of administration:

For cutaneous use, for the treatment of candidal vaginitis and candidal balanitis. The cream should be applied to the vulva and surrounding area. It can also be applied to the sexual partner's penis.

A doctor should be consulted if symptoms do not improve within 7 days.

4.3 Contraindications

Known hypersensitivity to any of the components.

4.4 Special warnings and precautions for use

To be used only if candidal vulvitis has previously been confirmed by a doctor.

The patient should be referred for medical advice if:

1. Previous history of STD or exposure to partner with STD.

2. More than two previous attacks in the last 6 months.

3. Known hypersensitivity to imidazoles or other vaginal antifungal products.

4. Pregnancy or suspected pregnancy.

5. Patients aged less than 16 or over 60.

6. Any abnormal or irregular vaginal bleeding.

7. Any blood staining of a vaginal or penile discharge.

8. Any vulval, vaginal or penile sores, ulcers or blisters.

9. Any associated lower abdominal pain or dysuria

10. No improvement in 7 days.

11. Any adverse effects such as redness, irritation or swelling associated with the treatment

The cream contains cetyl alcohol and stearyl alcohol, which may cause local skin reaction (e.g. contact dermatitis)

4.5 Interaction with other medicinal products and other forms of interaction

When used together, this product may cause damage to latex contraceptives. Consequently the effectiveness of such contraceptives may be reduced. Patients should be advised to use alternative precautions for at least 5 days after using the product.

4.6 Pregnancy and lactation


Data on a large number of exposed pregnancies indicate no adverse effects of Clotrimazole on pregnancy or on the health of the foetus/newborn child. To date, no other relevant epidemiological data are available.

Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife.


It is unknown whether clotrimazole is excreted in breast milk, so it should be given with caution to lactating mothers.

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible.

Immune system disorders: allergic reaction (syncope, hypotension, dyspnoea, urticaria)

Skin and subcutaneous tissue disorders: blisters, discomfort/pain, oedema, irritation, peeling/exfoliation, pruritus, rash, stinging/burning

4.9 Overdose

In the event of accidental oral ingestion, gastric lavage is rarely required and should be considered only if a life-threatening amount of clotrimazole has been ingested within the preceding hour or if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). It should be carried out only if the airway can be protected adequately.

5. Pharmacological properties
5.1 Pharmacodynamic properties

ATC code: D01A C 01

Clotrimazole is an imidazole derivative with a broad spectrum of antimycotic activity. It also exhibits activity against Trichomonas, staphylococci, streptococci and Bacteroides. It has no effect on lactobacilli.

Mechanism of action

Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the cytoplasmic membrane.

Pharmacodynamic effects

Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.

The mode of action of clotrimazole is fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. In-vitro activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive.

Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.

5.2 Pharmacokinetic properties

Pharmacokinetic investigations after dermal application have shown that clotrimazole is minimally absorbed from the intact or inflamed skin into the human blood circulation. The resulting peak serum concentrations of clotrimazole were below the detection limit of 0.001 mcg/ml, suggesting that clotrimazole applied topically is unlikely to lead to measurable systemic effects or side effects.

5.3 Preclinical safety data

There are no preclinical data of reference to the prescriber which are additional to the information included in other sections of the SPC.

6. Pharmaceutical particulars
6.1 List of excipients

Sorbitan stearate

Polysorbate 60

Cetyl palmitate

Stearyl alcohol

Cetyl alcohol


Benzyl alcohol

Purified water

6.2 Incompatibilities

None known

6.3 Shelf life

36 months

6.4 Special precautions for storage

No special precautions for storage

6.5 Nature and contents of container

Aluminium tube with polypropylene screw-on cap containing 20g of cream.

Thrush Duo pack only: Aluminium tube with polypropylene screw-on cap containing 20g of cream and PVC/Aluminium blisters containing 1 capsule.

6.6 Special precautions for disposal and other handling


7. Marketing authorisation holder

Teva UK Limited

Brampton Road

Hampden Park


East Sussex

BN22 9AG

8. Marketing authorisation number(s)

PL 00289/1476

9. Date of first authorisation/renewal of the authorisation

28/10/2005 / 07/06/2010

10. Date of revision of the text